This article is for informational and educational purposes only and does not constitute medical advice. Pinealon is supplied by Wholesale Peps as lyophilized research-grade material for in vitro laboratory use only and is not approved by the FDA for human or veterinary use.
Pinealon is a synthetic tripeptide composed of glutamic acid, aspartic acid, and arginine (Glu-Asp-Arg; single-letter: EDR), developed by the research group of Vladimir Khavinson at the St. Petersburg Institute of Bioregulation and Gerontology. It belongs to the peptide bioregulator class — a series of short synthetic peptides proposed to modulate gene expression in a tissue-specific manner by interacting with DNA regulatory elements. Cell-based and animal model studies, conducted predominantly within the Khavinson laboratory, have reported associations between Pinealon exposure and neuroprotective effects in oxidative stress models, antioxidant enzyme activity, and proposed modulation of gene expression pathways relevant to aging and neurodegeneration. Computational (in silico) studies have additionally examined EDR’s potential interactions with gene promoter sequences associated with Alzheimer’s disease pathways. No peer-reviewed clinical trials evaluating Pinealon in human subjects have been published; all available mechanistic and pharmacological evidence derives from cell-based assays, animal studies, and molecular docking analyses.
1. Background
1.1 Peptide Bioregulators — The Khavinson Class
The peptide bioregulator concept originates with Vladimir Khavinson and colleagues at the Institute of Bioregulation and Gerontology in St. Petersburg, whose work from the 1970s onward proposed that very short peptides, typically two to four residues, could regulate gene expression in a tissue-targeted way. Pinealon sits at the neurological end of that programme: a tripeptide modeled on pineal and brain tissue and studied for neuronal rather than systemic endpoints, which is why most of its literature concerns cultured neurons under oxidative stress rather than the aging-biology framing applied to the class as a whole.
The class includes a range of named compounds, each proposed to target specific tissue types: Epithalon (Ala-Glu-Asp-Gly) for the pineal gland, Cortagen (Ala-Glu-Asp-Pro) for the nervous system, Vilon (Lys-Glu) for immune regulation, Livagen for hepatic tissue, and Pinealon (Glu-Asp-Arg) for pineal gland and neuroprotective applications, among others. The biological rationale for tissue specificity — why a tripeptide would preferentially influence gene expression in one tissue over another following systemic administration — has not been mechanistically established through independent research [2].
1.2 The Pineal Gland and Neurological Aging
The pineal gland is a small neuroendocrine structure in the epithalamus that produces melatonin in response to light-dark cycles and plays a central role in circadian rhythm regulation. Beyond circadian biology, the pineal gland has been implicated in aging research: melatonin has antioxidant properties, and pineal function declines with age in parallel with reductions in nocturnal melatonin output. These observations have motivated interest in peptides proposed to support pineal gland regulatory biology.
Pinealon’s development within the Khavinson group was based on the hypothesis that a short peptide modeled on pineal gland-derived sequences could support pineal and nervous system gene expression programs relevant to neuroprotection and aging. The specific relationship between the EDR sequence and endogenous pineal peptide content has not been independently characterized.
1.3 Historical and Research Context
Pinealon’s published record is narrower than its reputation suggests. The most frequently cited experimental work is the 2012 cell-culture study by Linkova and colleagues in Bulletin of Experimental Biology and Medicine [3], with a 2021 computational analysis in Molecules addressing Alzheimer-associated pathways. Both come from the originating group, and no laboratory outside it has published a replication of the neuroprotective observations. That concentration matters more for a neurological compound than it might elsewhere, because neuroprotective effects are notoriously sensitive to model choice and assay conditions [1].
2. Molecular Structure
Pinealon is a tripeptide with the sequence Glu-Asp-Arg, abbreviated in single-letter code as EDR. At three residues it is among the shortest peptides in the research peptide class.
| Property | Detail |
|---|---|
| Full name | L-α-Glutamyl-L-α-aspartyl-L-arginine |
| Sequence (single-letter) | EDR |
| Length | 3 amino acids (tripeptide) |
| Molecular weight | ~433 Da |
| Net charge (physiological pH) | Mixed: two acidic residues (Glu, Asp) and one strongly basic (Arg) |
| Post-translational modifications | None; fully synthetic |
| Water solubility | High |
| Class | Peptide bioregulator (Khavinson group) |
The Arg residue at the C-terminus is of particular interest to the Khavinson group’s proposed DNA-binding mechanism, as arginine’s guanidinium side chain is capable of electrostatic interaction with the phosphate backbone of DNA and hydrogen bonding with nucleobases in the major groove. Whether the EDR tripeptide interacts with genomic DNA in the manner proposed — and whether such interaction, if it occurs, is sufficient to alter transcription at physiologically meaningful concentrations — has not been independently established [2].
3. Proposed Mechanisms
The mechanisms below have been proposed in cell-based, animal model, and computational studies. None has been confirmed in controlled human interventional research. All mechanistic claims originate predominantly from the Khavinson group.
4. Key Research Findings
| Research Area | Evidence Level | Best Available Evidence |
|---|---|---|
| Neuroprotection / anti-apoptotic | Limited Cell-based only |
Linkova et al. 2012 (Bull Exp Biol Med) |
| DNA interaction / gene expression | Limited In silico + cell-based |
Khavinson et al. 2012 (Bull Exp Biol Med) |
| Alzheimer’s-related gene pathways | Limited In silico (computational) |
Khavinson et al. 2021 (Molecules) |
| Antioxidant enzyme activity | Limited Cell-based only |
Khavinson group; multiple studies |
| Retinal / visual system neuroprotection | Limited Animal models, cell-based |
Limited published literature |
| Pineal / melatonin pathway modulation | Limited In silico only |
Bioinformatic analyses; no in vivo data |
4.1 Neuroprotection in Oxidative Stress Models
Linkova et al. (2012) reported that EDR tripeptide treatment was associated with increased neuronal and glial cell viability in cultures exposed to oxidative stress conditions, compared with untreated controls [1]. Reduced markers of apoptosis were reported alongside increased antioxidant enzyme activity in treated cultures. These cell-based findings represent the primary experimental evidence for Pinealon’s proposed neuroprotective properties and form the basis for much of the subsequent characterization of the compound.
Schematic representation based on approximate in vitro cell viability findings reported by Linkova et al. (2012) [1]. Values are illustrative approximations and should not be interpreted as precise experimental data. Not derived from human or in vivo studies.
4.2 DNA Interaction and Gene Expression
Khavinson et al. (2012) described the proposed mechanism by which short peptides including EDR interact with DNA. Using molecular modeling and docking analyses, the group proposed that short bioregulator peptides bind to specific nucleotide sequences in promoter regions of target genes, with the arginine guanidinium group forming interactions with the DNA major groove. This binding was proposed to modulate transcription factor access and thereby regulate gene expression [2].
The authors reported that different di- and tripeptide sequences showed preferential affinity for different DNA sequences in silico, providing the theoretical basis for the claimed tissue-specificity of different bioregulator peptides. The applicability of these in silico binding affinities to transcriptional regulation in living cells — where peptides must compete with histones, transcription factors, and other DNA-binding proteins at much higher effective concentrations — has not been independently verified.
4.3 Computational Studies and Alzheimer’s Disease Pathways
Khavinson et al. (2021) applied computational molecular docking analysis to examine potential interactions between the EDR peptide and the promoter sequences of genes relevant to Alzheimer’s disease pathology, including genes involved in amyloid precursor protein (APP) processing and tau regulation [3]. The authors proposed that EDR binding at these promoter sites could theoretically modulate expression of Alzheimer’s-related genes, positioning the peptide as a candidate for further experimental study in neurodegeneration models.
This in silico study represents hypothesis generation rather than experimental evidence of activity. The transition from in silico docking affinity to measurable transcriptional changes in relevant cell models — and from there to any meaningful outcome in animal models of neurodegeneration — involves multiple unvalidated steps.
5. Evidence Status
| Evidence Type | Current Status |
|---|---|
| Cell-based neuroprotection in oxidative-stress models | Published (Linkova et al. 2012, Bulletin of Experimental Biology and Medicine) |
| Computational pathway analysis (Alzheimer-associated targets) | Published (Khavinson et al. 2021, Molecules) — in silico only |
| In silico docking to gene promoter sequences | Published; predicted binding geometry, not experimentally confirmed |
| Antioxidant enzyme activity in neuronal preparations | Reported in cell and animal work from the originating group |
| Controlled animal studies of cognition or neuroprotection | Limited; no independent replication identified |
| Blood-brain barrier penetration by intact EDR | Not characterized in any published pharmacokinetic study |
| Human safety, pharmacokinetics or efficacy | No published trial at any phase |
| Independent replication of any key finding | Not identified |
What We Still Don’t Know
- Whether the proposed DNA-binding mechanism operates in living cells: The in silico docking analyses propose a specific mechanism, but whether EDR at pharmacologically achievable intracellular concentrations actually binds to genomic DNA promoter sequences — in the presence of competing histones, transcription factors, and chromatin structure — has not been demonstrated experimentally by independent investigators.
- Whether tissue specificity exists and how it would operate: The claim that Pinealon preferentially targets pineal and neural tissue is central to its classification as a peptide bioregulator, but the cellular and molecular basis for any such specificity following systemic administration has not been established.
- Human safety and pharmacokinetics: No published phase 1 trial characterizes the safety, tolerability, half-life, or target tissue distribution of Pinealon in humans. As a tripeptide, it would be expected to undergo rapid hydrolysis in plasma, but pharmacokinetic data in humans are absent.
- Whether in vitro neuroprotection findings translate in vivo: Cell viability improvements under acute oxidative stress in culture are a common finding for many compounds that subsequently show no effect in whole-animal or human studies. The translational value of the reported in vitro effects has not been tested in controlled animal experiments by independent groups.
- Effective dose and route of administration in any in vivo context: Dose-response data in animal models and the pharmacologically active concentration range in vivo are not characterized in the independent literature.
- Whether Alzheimer’s disease-relevant in silico findings have experimental correlates: The computational analysis proposing interactions with APP and tau-related gene promoters has not been followed by published experimental validation in cell or animal models of Alzheimer’s disease.
6. Limitations of Current Research
References
- Linkova NS, Khavinson VKh, Yuzhakov VV, Rubtsova GV, Tarnovskaya SI. "Neuroprotective Activity of Tripeptide Glu-Asp-Arg." Bulletin of Experimental Biology and Medicine. 2012;153(3):358–361. doi:10.1007/s10517-012-1717-7
- Khavinson VKh, Tarnovskaya SI, Linkova NS, Pronyaeva VE, Kolchina NV, Yakutseni PP. "Mechanism of Biological Activity of Short Peptides: Interaction with DNA, Regulation of Gene Expression." Bulletin of Experimental Biology and Medicine. 2012;154(1):63–65. doi:10.1007/s10517-012-1882-8
- Khavinson V, Linkova N, Kozhevnikova E, Trofimova S. "EDR Peptide: Possible Mechanism of Gene Expression and Protein Synthesis Regulation Involved in the Pathogenesis of Alzheimer’s Disease." Molecules. 2021;26(8):2131. doi:10.3390/molecules26082131
- Tarnovskaya SI, Khavinson VKh, Linkova NS, Pronyaeva VE, Kolchina NV, Tendler SM. "Mechanism of Short Peptides Interaction with DNA." Advances in Gerontology. 2014;27(4):706–714.